Teva was fined 60 million euros by the European Union - "We will appeal"

Teva was fined 60 million euros by the European Union, in light of an agreement signed between it and Seflon in 2005 and ended in 2011, when Teva acquired Seflon for $ 6.8 billion in cash.
The agreement between Teva and Ceflon led to the postponement of the launch of a generic version of Ceplon's best-selling drug Provigil for the treatment of narcolepsy. This drug provided at its peak 40% of Cephalon's revenue turnover. As part of the agreement, known as Pay For Delay, Teva refrained from launching a generic version of the drug in exchange for a cash payment and other commercial benefits it received from Teflon.
The EU decision to fine Teva and Ceflon (each will pay 30 million euros) was made following a nine-year investigation, as part of an EU attempt to attack such agreements on the grounds that they artificially raise drug prices and allow companies that developed the original drug and companies that develop versions Its generic, rake in excess profits at the expense of the consumer and the health budgets of EU countries.
Teva announced that it would appeal the EU decision, noting that it continues to believe that the patent claims arrangement between it and Seflon from 2005 did not violate European antitrust law.
Seflon and the Pay For Delay deal have in the past caused heavy legal damages to Teva, when it had to pay $ 1.2 billion in May 2015 to settle claims by the U.S. Antitrust Authority, wholesalers and retailers of drugs. These sources claimed that even before it was acquired by Teva, Seflon reached agreements with generic companies, including Teva, in which it paid the generic companies $ 200 million to delay the launch of generic versions of the drug Provigil for the treatment of narcolepsy. This drug was Seflon's main profit center before its purchase.